Zhangjiang pharma firm, US cancer center sign co-op agreement


Ascentage Pharma, from Zhangjiang Pharma Valley, and the University of Texas MD Anderson Cancer Center, signed a five-year strategic cooperation agreement on Jan 7.

Ascentage Pharma is a globally-focused, clinical-stage biopharmaceutical company developing novel small molecule therapies for cancers, hepatitis B and age-related diseases.

MD Anderson Cancer Center is one of the world’s most renowned cancer centers, aiming at providing care, research, education and prevention for cancer patients and their families.

The two sides will conduct joint research in oncology to advance the clinical development of five new drugs, which are under development.

"We will work together with the MD Anderson team to accelerate the clinical development of related products and provide new treatment options for cancer patients worldwide at an early date," said Yang Dajun, chairman of Ascentage Pharma.

Hagop Kantarjian, M.D., director of the leukemia department of MD Anderson, whose previous research has led to the approval of more than 20 leukemia drugs by the United States. Food and Drug Administration, will be the director of the cooperation between the two sides.